According to a recent study, $5.8 billion was spent in 1 year on the unnecessary prescription of brand-name statins.
Formulary Watch
Latest News
All News
Advertisement
Middle-aged women with RLS may be at higher risk of developing high blood pressure, according to a study published online October 10 in Hypertension: Journal of the American Heart Association.
FDA has approved bupivacaine hydrochloride injection, USP (Sagent and Strides Arcolab), a local or regional anesthetic, for use in surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and obstetrical procedures.
Vivus has resubmitted its New Drug Application (NDA) for Qnexa (phentermine/topiramate) to FDA.
FDA has approved deferiprone (Ferriprox, ApoPharma) to treat patients with iron overload resulting from blood transfusions in patients with thalassemia who had an inadequate response to previous chelation therapy.
In patients with relapsing forms of MS, once-daily oral teriflunomide 14 mg significantly reduced the annual relapse rate and disability progressions, and improved several MRI measures of disease activity, according to a study recently published in The New England Journal of Medicine.
Saw palmetto fruit extract has no effect on lower urinary tract (UT) symptoms attributed to BPH, regardless of dose, a study published in The Journal of the American Medical Association finds.
Novartis has filed for marketing authorization with the European Medicines Agency of its investigational drug, NVA237 (glycopyrronium bromide), the drug company announced at the European Respiratory Society in Amsterdam, The Netherlands.
Asthma may contribute to poor glycemic control in youth with diabetes, especially if the disease is left untreated, according to the results of a study published online September 26 in Pediatrics.
There is a strong relationship between bivalirudin dosing requirements and renal function when steady state conditions are maintained, results of a study published in the September issue of Pharmacotherapy demonstrate.
Advertisement
The AAP and the CDC have have amended and expanded their recommendations for the use of Tdap, according to a policy statement published online September 26 in Pediatrics.
An FDA Drug Safety Communication sent to healthcare professionals states that Dasatinib (Sprycel, Bristol-Myers Squibb) may increase the risk of pulmonary arterial hypertension.
FDA has approved ipratropium bromide and albuterol (Combivent Respimat Inhalation Spray, Boehringer Ingelheim), for COPD patients using a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
FDA has approved sitagliptin and simvastatin (Juvisync, MSD International GmbH Clonmel), a fixed-dose combination prescription medication that contains 2 previously approved medications in 1 tablet for use by adults who need both sitagliptin and simvastatin.
FDA has approved tadalafil (Cialis, Eli Lilly) for 3 indications: ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions.
FDA has approved tadalafil (Cialis, Eli Lilly) for 3 indications: ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions.
Osteoporosis: A review of current recommendations and emerging treatment options; Focus On Dapagliflozin: An emerging treatment option for type 2 diabetes mellitus
Drug companies sponsoring human trials of possible new medications have ethical responsibilities to study participants and to science to disclose the results of their clinical research, even when product development is no longer being pursued.
New molecular entity: Ticagrelor tablets were FDA approved to reduce rate of thrombotic cardiovascular events in patients with ACS.
Dapagliflozin is a sodium glucose co-transporter inhibitor under review for FDA approval for the treatment of type 2 diabetes mellitus. Despite the availability of many antidiabetic agents in the United States, type 2 diabetes remains inadequately controlled in many patients.
FDA is requiring the zoledronic acid (Reclast, Novartis) prescribing information to now include a warning not to use the drug in those with renal dysfunction.
It's flu season again, which always focuses public attention on the reliablity and availability of the nation's vaccine supply.
In sexually active partners, early treatment with antiretroviral therapy compared to delayed treatment decreased the risk of genetically linked HIV-1 transmission to the uninfected partner.
Axitinib, an investigational selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 significantly extended progression-free survival compared with sorafenib in patients with previously treated metastatic renal cell carcinoma.
Diarrhea-associated healthcare utilization and treatment costs for US children <5 years of age
Recent FDA action (through September 2011) related to golimumab expanded label, meningococcal and Hib combination vaccine, desvenlafaxine, rivaroxaban anticoagulant, deferiprone oral iron chelator, glucarpidase experimental treatment, doxidopa, QLT091001, NP-001, cyclophosphamide, resminostat oral pan HDAC inhibitor, TXA127
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Myqorzo is now available for rare heart condition at a $108,400 annual price
3
Medicaid tech companies pledge $600 million to help states update systems
4
Why the great pharma-MedTech divide is healthcare’s biggest miss
5